Avenue Therapeutics (ATXI) Stock Price, News & Analysis

Company Overview

Avenue Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.

The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain. Avenue has completed pivotal Phase 3 clinical trials and submitted a New Drug Application to the U.S. Food and Drug Administration, seeking approval to introduce the first IV tramadol formulation in the United States. If approved, the therapy is expected to offer clinicians an alternative to existing intravenous opioids while leveraging a lower potential for respiratory depression and abuse.

Avenue Therapeutics is headquartered in the United States and conducts its operations through collaborations with contract research organizations and commercial partners. The company is led by a management team with extensive experience in pharmaceutical development, regulatory strategy and product commercialization, and it continues to explore additional central nervous system pipeline opportunities designed to leverage its formulation expertise and address high-unmet medical needs.

Key Stats

• Today's Range: $0.71 to $0.84
• 50-Day Range: $0.31 to $0.90
• 52-Week Range: $0.17 to $2.70
• Volume: 1,453 shs
• Average Volume: 143,965 shs
• Market Capitalization: $2.68 million
• P/E Ratio: 0.05
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Avenue Therapeutics Stock Analysis - MarketRank™

Avenue Therapeutics scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Avenue Therapeutics.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Avenue Therapeutics is 0.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 231.90.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avenue Therapeutics is 0.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.12.

Price to Book Value per Share Ratio

Avenue Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.31% of the outstanding shares of Avenue Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Avenue Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avenue Therapeutics has recently decreased by 14.17%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avenue Therapeutics does not currently pay a dividend.

Dividend Growth

Avenue Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.99

Percentage of Shares Shorted

1.31% of the outstanding shares of Avenue Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Avenue Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Avenue Therapeutics has recently decreased by 14.17%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Avenue Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

2 people have added Avenue Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.80% of the stock of Avenue Therapeutics is held by insiders.

Percentage Held by Institutions

Only 17.34% of the stock of Avenue Therapeutics is held by institutions.

ATXI Stock Analysis - Frequently Asked Questions

How have ATXI shares performed this year?

Avenue Therapeutics' stock was trading at $2.00 on January 1st, 2025. Since then, ATXI shares have decreased by 57.9% and is now trading at $0.8428.

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) issued its earnings results on Friday, August, 9th. The company reported ($6.43) earnings per share for the quarter, missing analysts' consensus estimates of ($1.05) by $5.38.

When did Avenue Therapeutics' stock split?

Shares of Avenue Therapeutics reverse split on the morning of Friday, April 26th 2024.The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

When did Avenue Therapeutics IPO?

Avenue Therapeutics (ATXI) raised $30 million in an initial public offering on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.

How do I buy shares of Avenue Therapeutics?

Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Avenue Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avenue Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), GE Aerospace (GE), CrowdStrike (CRWD) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 8/09/2024
• Today: 10/14/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATXI
• CIK: 1644963
• Web: www.avenuetx.com
• Phone: (781) 652-4500
• Fax: N/A
• Employees: 4
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): ($0.95)
• Trailing P/E Ratio: 0.05
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -471.57%
• Return on Assets: -296.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.70
• Quick Ratio: 2.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.92 per share
• Price / Book: 0.44

Miscellaneous

• Outstanding Shares: 3,183,000
• Free Float: 2,017,000
• Market Cap: $2.68 million
• Optionable: Not Optionable
• Beta: 0.04